Quest Diagnostics (DGX) Tops Q2 EPS by 210c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- Lula, Brazil's iconic working class president, wins historic fourth term in dramatic comeback
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
- Accenture shares fall on insider sales and analyst downgrade
- Wall Street closes lower to end rocky week
- Credo Technology shares fall on competition concerns
Quest Diagnostics (DGX) PT Raised to $160 at Jefferies
July 23, 2021 8:44 AM EDTJefferies analyst Brian Tanquilut raised the price target on Quest Diagnostics (NYSE: DGX) to $160.00 (from $155.00) while maintaining a Buy rating.
The analyst commented, "e are positive on DGX given our view that continued improvement in core fundamentals -- driven by accelerating payor-driven... More



